Your search for ‘Smart & Biggar’ returned 2,497 results

This is the second decision involving copyright for which the Supreme Court has granted leave to appeal in the last six months.

On June 1, 2016, Madam Justice Tremblay-Lamer of the Federal Court issued an interlocutory injunction against retailers of set-top boxes that are configured, or "pre-loaded", with various applications that provide their users with unauthorized access to copyrighted television content.

Implementation of the enhanced system to combat counterfeiting at the Canadian border continues. On January 1, 2015 provisions came into effect which provide Canada customs authorities with the ability to detain suspected counterfeit or pirated products ..

The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2015, updating our 2015 mid-year highlights.

The wind of change blew through Canada's various intellectual property laws in 2014, changing many of their fundamental concepts and related practices. The following changes were the most noteworthy.

On June 9, 2015, the Competition Bureau released an update to its draft Intellectual Property Enforcement Guidelines for comment.

In Canadian trademark opposition proceedings, the legal burden is on the party applying to register the trademark to demonstrate, on a balance of probabilities, that its trademark is registrable.

Manufacturers of Internet of Things (IoT) devices (e.g., lights, doorbells, locks, cameras, watches, health trackers, etc.) are responsible for ensuring compliance with Canadian privacy legislation.

Starting in 2006, Apotex manufactured perindopril tablets in Canada, and sold these in Canada and to its UK and Australian affiliates.

The Canadian government just announced $450 million in financial support for research institutes, such as those at hospitals and universities.

The European Medicines Agency made its biosimilar monoclonal antibody guidelines effective in December 2012.

Intellectual property strategy is fundamental to the successful development and commercialization of a personalized therapeutic and its companion diagnostic.

Like other patents in Canada, drug patents have a term limited to twenty years from the filing date.

The Federal Court has dismissed a request to certify a proposed class proceeding against a large number of generic...

On November 20, 2019, the Federal Court (FC) issued its reconsideration decision on the quantum of damages owed by Apotex for its infringement of eight Eli Lilly process...

Catalyst Pharmaceuticals, Inc (Catalyst) filed a new drug submission (NDS) for FIRDAPSE one month before Médunik filed its NDS for RUZURGI.

In connection with Royal Assent of the Pharmacare Act, we previously reported that the Minister of Health intended to negotiate bilateral agreements with provinces and territories to provide universal.